Serevent, Advair, Foradil Withdrawals To Be Considered By Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pulmonary-Allergy Drugs Advisory Committee will vote July 13 whether currently available data support continued marketing of the long-acting beta-agonist bronchodilators. Committee will also consider labeling changes for formoterol concerning severe asthma exacerbations.
You may also be interested in...
Risk/Benefit Of Asthma Drugs To Be Debated At Future Advisory Committee
FDA awaits data from controlled trials of seven long-acting beta agonists before bringing them back for panel review later this year.
Risk/Benefit Of Asthma Drugs To Be Debated At Future Advisory Committee
FDA awaits data from controlled trials of seven long-acting beta agonists before bringing them back for panel review later this year.
Evaluation Of Drug Benefits Needs Quantitative Measures, FDA's Graham Says
Evidence-based standards currently applied to risk should be applied to benefit, the FDAer adds.